This inventor holds 1 USPTO granted patent. Top assignee: Jilin University. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Innovations of Hongqiang Lin in Anti-Colitis Drug Development
Introduction
Hongqiang Lin is a notable inventor based in Changchun, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for inflammatory bowel disease. His innovative work has led to the creation of a promising anti-colitis drug.
Latest Patents
Hongqiang Lin holds a patent titled "Use of oleanolic acid-28-O-beta-D-glucopyranoside in preparation of anti-colitis drug." This patent describes the use of oleanolic acid-28-O-β-D-glucopyranoside, which exhibits significant anti-ulcerative colitis activity compared to its parent compound, oleanolic acid, and other analogues. The efficacy of this compound is comparable to Mesalazine, a first-line treatment for inflammatory bowel disease, while also minimizing the risk of salicylic acid anaphylaxis associated with Mesalazine treatment. This innovation presents a promising application prospect in the pharmaceutical industry.
Career Highlights
Hongqiang Lin is affiliated with Jilin University, where he continues to engage in research and development in the field of medicinal chemistry. His work has garnered attention for its potential impact on the treatment of gastrointestinal disorders.
Collaborations
Hongqiang Lin collaborates with esteemed colleagues, including Haoming Lv and Fang Wang, who contribute to his research endeavors. Their combined expertise enhances the quality and scope of their projects.
Conclusion
Hongqiang Lin's innovative approach to developing an anti-colitis drug showcases his dedication to improving healthcare solutions. His contributions to the field of pharmaceuticals are noteworthy and hold great promise for future advancements in treating inflammatory bowel disease.